Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors

This study will explore whether tirzepatide is a practical and acceptable treatment for postmenopausal females with a history of hormone receptor-positive breast cancer and obesity. The investigators aim to understand whether participants are willing and able to take this medication once weekly for 6 months and whether it may help improve weight and overall health. There will be monthly check-ins to monitor progress and safety. At the beginning and end of the study, participants will undergo body composition assessments, blood tests and a stool sample will be collected, and surveys will be com

Trial Details

NCT ID

NCT07257484

Phase

PHASE4

Sponsor

Weill Medical College of Cornell University

Status

RECRUITING

Cancer Type

ER/PR Positive (Hormone Receptor Positive) Breast Cancer

Interventions

• Tirzepatide

Locations (sample)

• New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

• Biologically female
• Obesity as defined by current BMI ≥ 30 kg/m²
• Postmenopausal as defined by one or more of the following
• Age ≥60 years

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find ER/PR Positive (Hormone Receptor Positive) Breast Cancer Trials on Trialify →